Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BETA Technologies, Inc.BETA · Entity 1930 | Director | June 11, 2026 | June 12, 2026 |
| UNITED THERAPEUTICS CorpUTHR · Entity 664 | Director · Chairperson & CEO | October 13, 2026 | October 14, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BETA Technologies, Inc.
Report date June 11, 2026 · Filed June 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A common stockSEC Table I · non-derivative | Direct | 8,213 |
Reported balance
After 2026-06-11 transaction · row 1
1 source rowRow 1 · 2026-06-11 · Grant · Acquired 7,142 · Balance 8,213 |
UNITED THERAPEUTICS Corp
Report date October 13, 2026 · Filed October 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Indirectby Trust | 333,943 |
Reported balance
After 2026-10-13 transaction · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · 2026-10-13 · Exercise / conversion · Acquired 9,500 · Balance 333,943 F1: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026. F2: Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries. |
| Common StockSEC Table I · non-derivative | Indirectby Trust | 333,304 |
Reported balance
After 2026-10-13 transaction · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · 2026-10-13 · Sale · Disposed 639 · Balance 333,304 F1: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026. F3: This transaction was executed in multiple trades at prices ranging from $542.06 to $543.05. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2: Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries. |
| Common StockSEC Table I · non-derivative | Indirectby Trust | 330,964 |
Reported balance
After 2026-10-13 transaction · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · 2026-10-13 · Sale · Disposed 2,340 · Balance 330,964 F1: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026. F4: This transaction was executed in multiple trades at prices ranging from $543.06 to $544.05. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2: Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries. |
| Common StockSEC Table I · non-derivative | Indirectby Trust | 329,472 |
Reported balance
After 2026-10-13 transaction · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · 2026-10-13 · Sale · Disposed 1,492 · Balance 329,472 F1: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026. F5: This transaction was executed in multiple trades at prices ranging from $544.08 to $545.06. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2: Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries. |
| Common StockSEC Table I · non-derivative | Indirectby Trust | 327,965 |
Reported balance
After 2026-10-13 transaction · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · 2026-10-13 · Sale · Disposed 1,507 · Balance 327,965 F1: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026. F6: This transaction was executed in multiple trades at prices ranging from $545.08 to $546.07. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2: Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries. |
| Common StockSEC Table I · non-derivative | Indirectby Trust | 326,513 |
Reported balance
After 2026-10-13 transaction · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · 2026-10-13 · Sale · Disposed 1,452 · Balance 326,513 F1: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026. F7: This transaction was executed in multiple trades at prices ranging from $546.08 to $547.06. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2: Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries. |
| Common StockSEC Table I · non-derivative | Indirectby Trust | 325,883 |
Reported balance
After 2026-10-13 transaction · row 7
Holding and transaction disclosures are not merged.
1 source rowRow 7 · 2026-10-13 · Sale · Disposed 630 · Balance 325,883 F1: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026. F8: This transaction was executed in multiple trades at prices ranging from $547.08 to $547.96. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2: Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries. |
| Common StockSEC Table I · non-derivative | Indirectby Trust | 325,185 |
Reported balance
After 2026-10-13 transaction · row 8
Holding and transaction disclosures are not merged.
1 source rowRow 8 · 2026-10-13 · Sale · Disposed 698 · Balance 325,185 F1: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026. F9: This transaction was executed in multiple trades at prices ranging from $548.12 to $549.11. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2: Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries. |
| Common StockSEC Table I · non-derivative | Indirectby Trust | 324,683 |
Reported balance
After 2026-10-13 transaction · row 9
Holding and transaction disclosures are not merged.
1 source rowRow 9 · 2026-10-13 · Sale · Disposed 502 · Balance 324,683 F1: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026. F10: This transaction was executed in multiple trades at prices ranging from $549.25 to $550.01. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2: Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries. |
| Common StockSEC Table I · non-derivative | Indirectby Trust | 324,523 |
Reported balance
After 2026-10-13 transaction · row 10
Holding and transaction disclosures are not merged.
1 source rowRow 10 · 2026-10-13 · Sale · Disposed 160 · Balance 324,523 F1: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026. F11: This transaction was executed in multiple trades at prices ranging from $550.31 to $551.03. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2: Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries. |
| Common StockSEC Table I · non-derivative | Indirectby Trust | 324,443 |
Reported balance
After 2026-10-13 transaction · row 11
Holding and transaction disclosures are not merged.
1 source rowRow 11 · 2026-10-13 · Sale · Disposed 80 · Balance 324,443 F1: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026. F12: This transaction was executed in multiple trades at prices ranging from $551.37 to $551.61. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2: Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries. |
| Common StockSEC Table I · non-derivative | Indirectby Trust | 249,108 |
Reported balance
Holding disclosure · report date 2026-10-13 · row 14
Holding and transaction disclosures are not merged.
1 source rowRow 14 · Balance 249,108 F13: Shares held in family trusts as to which the Reporting Person's spouse is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke. |
| Common StockSEC Table I · non-derivative | Indirectby Trust | 45,596 |
Reported balance
Holding disclosure · report date 2026-10-13 · row 15
Holding and transaction disclosures are not merged.
1 source rowRow 15 · Balance 45,596 F14: Shares held in family trusts as to which the Reporting Person's spouse shares investment power and the Reporting Person and/or immediate family members are beneficiaries. |
| Common StockSEC Table I · non-derivative | Indirectby Trust | 8,902 |
Reported balance
Holding disclosure · report date 2026-10-13 · row 16
Holding and transaction disclosures are not merged.
1 source rowRow 16 · Balance 8,902 F15: Shares held in family trusts as to which the Reporting Person is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $117.76 · Expires 2027-03-15 | Indirectby Trust | 242,910 |
Reported balance
After 2026-10-13 transaction · row 17
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 17 · 2026-10-13 · Exercise / conversion · Disposed 9,500 · Balance 242,910 F1: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026. F16: These stock options vested in equal one-third installments on March 15, 2021, 2022 and 2023. F17: Stock options held in a family trust as to which the Reporting Person shares investment power and the Reporting Person and immediate family members are beneficiaries. |
| Common StockSEC Table I · non-derivative | Direct | 40,513 |
Reported balance
Holding disclosure · report date 2026-10-13 · row 12
Holding and transaction disclosures are not merged.
1 source rowRow 12 · Balance 40,513 |
| Common StockSEC Table I · non-derivative | Indirectby Spouse | 166 |
Reported balance
Holding disclosure · report date 2026-10-13 · row 13
Holding and transaction disclosures are not merged.
1 source rowRow 13 · Balance 166 |
Filing footnotes · ownership attribution and instrument terms
F1: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026.
F10: This transaction was executed in multiple trades at prices ranging from $549.25 to $550.01. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F11: This transaction was executed in multiple trades at prices ranging from $550.31 to $551.03. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F12: This transaction was executed in multiple trades at prices ranging from $551.37 to $551.61. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F13: Shares held in family trusts as to which the Reporting Person's spouse is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke.
F14: Shares held in family trusts as to which the Reporting Person's spouse shares investment power and the Reporting Person and/or immediate family members are beneficiaries.
F15: Shares held in family trusts as to which the Reporting Person is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke.
F16: These stock options vested in equal one-third installments on March 15, 2021, 2022 and 2023.
F17: Stock options held in a family trust as to which the Reporting Person shares investment power and the Reporting Person and immediate family members are beneficiaries.
F2: Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries.
F3: This transaction was executed in multiple trades at prices ranging from $542.06 to $543.05. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F4: This transaction was executed in multiple trades at prices ranging from $543.06 to $544.05. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F5: This transaction was executed in multiple trades at prices ranging from $544.08 to $545.06. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F6: This transaction was executed in multiple trades at prices ranging from $545.08 to $546.07. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F7: This transaction was executed in multiple trades at prices ranging from $546.08 to $547.06. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F8: This transaction was executed in multiple trades at prices ranging from $547.08 to $547.96. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F9: This transaction was executed in multiple trades at prices ranging from $548.12 to $549.11. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 19, 2019 Filed Mar 20, 2019 20:03 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Disposition to issuerCommon Stock | 4,755 | $118.73 | $564,553.07 |
DisclosureSEC source: 0001127602-19-012433 · form4.xml · nonDerivative · entry 6 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,440 F1 · kind: This exercise of share tracking awards was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. F5 · price: This transaction was executed in multiple trades at prices ranging from $118.25 to $119.24. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 19, 2019 Filed Mar 20, 2019 20:03 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 7,055 | $52.65 | $371,445.75 |
DisclosureSEC source: 0001127602-19-012433 · form4.xml · nonDerivative · entry 5 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,195 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of share tracking awards was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Read SEC document |
| March 18, 2019 Filed Mar 20, 2019 20:03 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionStock Options · Derivative | 7,055 | $0.00 Strike: $52.65 | $0.00 |
DisclosureSEC source: 0001127602-19-012433 · form4.xml · derivative · entry 10 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,055 Underlying: Common Stock · 7,055 shares Expires 2019-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of share tracking awards was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Read SEC document |
| March 18, 2019 Filed Mar 20, 2019 20:03 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Disposition to issuerCommon Stock | 211 | $119.18 | $25,147.63 |
DisclosureSEC source: 0001127602-19-012433 · form4.xml · nonDerivative · entry 4 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140 F1 · kind: This exercise of share tracking awards was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. F4 · price: This transaction was executed in multiple trades at prices ranging from $119.13 to $119.24. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 18, 2019 Filed Mar 20, 2019 20:03 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Disposition to issuerCommon Stock | 6,344 | $118.48 | $751,656.79 |
DisclosureSEC source: 0001127602-19-012433 · form4.xml · nonDerivative · entry 3 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 351 F1 · kind: This exercise of share tracking awards was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. F3 · price: This transaction was executed in multiple trades at prices ranging from $118.12 to $119.04. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 18, 2019 Filed Mar 20, 2019 20:03 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Disposition to issuerCommon Stock | 500 | $117.61 | $58,804.00 |
DisclosureSEC source: 0001127602-19-012433 · form4.xml · nonDerivative · entry 2 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,695 F1 · kind: This exercise of share tracking awards was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $117.07 to $118.03. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 18, 2019 Filed Mar 20, 2019 20:03 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 7,055 | $52.65 | $371,445.75 |
DisclosureSEC source: 0001127602-19-012433 · form4.xml · nonDerivative · entry 1 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,195 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of share tracking awards was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Read SEC document |
| March 15, 2019 Filed Mar 19, 2019 12:35 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | GrantStock Options · Derivative | 500,000 | $0.00 Strike: $117.76 | $0.00 |
DisclosureSEC source: 0001127602-19-011996 · form4.xml · derivative · entry 5 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2027-03-15 F1 · security: These stock options represent up-front equity grants covering four years of equity compensation for this named executive officer (2019 through 2022) and have been designed such that: (a) overall equity compensation expense on an annualized basis, and overall dilution, are both expected to be lower than if the Company had continued with the previous equity compensation program for four additional years; (b) the named executive officer will be incented to achieve the Company's business objectives over the four-year period; and (c) vesting is heavily weighted toward the end of the four-year period, in order to aid in retention over that timeframe. F4 · derivative.exercise_date: These stock options will vest in equal one-third installments on March 15, 2021, 2022 and 2023. Read SEC document |
| March 15, 2019 Filed Mar 19, 2019 12:35 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | GrantStock Options · Derivative | 500,000 | $0.00 Strike: $135.42 | $0.00 |
DisclosureSEC source: 0001127602-19-011996 · form4.xml · derivative · entry 4 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2027-03-15 F1 · security: These stock options represent up-front equity grants covering four years of equity compensation for this named executive officer (2019 through 2022) and have been designed such that: (a) overall equity compensation expense on an annualized basis, and overall dilution, are both expected to be lower than if the Company had continued with the previous equity compensation program for four additional years; (b) the named executive officer will be incented to achieve the Company's business objectives over the four-year period; and (c) vesting is heavily weighted toward the end of the four-year period, in order to aid in retention over that timeframe. F2 · derivative.exercise_price: Exercise price is equal to 115% of the closing price for the Company's common stock on the date of grant. F3 · derivative.exercise_date: This award will cliff vest (100%) on March 15, 2023. Read SEC document |
| February 27, 2019 Filed Feb 27, 2019 22:55 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | GrantStock Options · Derivative | 213,827 | $0.00 Strike: $111.00 | $0.00 |
DisclosureSEC source: 0001127602-19-008763 · form4.xml · derivative · entry 1 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 213,827 Underlying: Common Stock · 213,827 shares Expires 2028-03-15 F1 · security: These performance-based stock options were initially awarded on March 15, 2018, subject to a one-year performance condition tied to company-wide milestone performance for 2018, which was determined on February 27, 2019. Number of stock options reported represents the number of options earned based on milestone performance. F2 · derivative.exercise_date: These stock options vest in one-third increments on each of March 15, 2019, 2020 and 2021. Read SEC document |
| January 31, 2019 Filed Feb 1, 2019 13:54 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionStock Options · Derivative | 7,054 | $0.00 Strike: $52.65 | $0.00 |
DisclosureSEC source: 0001127602-19-003268 · form4.xml · derivative · entry 6 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,110 Underlying: Common Stock · 7,054 shares Expires 2019-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and corresponding sale of shares was pursuant to a Rule 10b5-1 trading plan (the "plan") entered into by the reporting person. The plan is designed to exercise and sell up to 148,138 stock options (which expire at the end of 2019) during the month of January 2019, in equal tranches of approximately 7,055 shares per day assuming certain conditions are met. Read SEC document |
| January 31, 2019 Filed Feb 1, 2019 13:54 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 100 | $115.97 | $11,597.00 |
DisclosureSEC source: 0001127602-19-003268 · form4.xml · nonDerivative · entry 3 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140 F1 · kind: This exercise of stock options and corresponding sale of shares was pursuant to a Rule 10b5-1 trading plan (the "plan") entered into by the reporting person. The plan is designed to exercise and sell up to 148,138 stock options (which expire at the end of 2019) during the month of January 2019, in equal tranches of approximately 7,055 shares per day assuming certain conditions are met. Read SEC document |
| January 31, 2019 Filed Feb 1, 2019 13:54 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 6,954 | $115.29 | $801,751.69 |
DisclosureSEC source: 0001127602-19-003268 · form4.xml · nonDerivative · entry 2 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 240 F1 · kind: This exercise of stock options and corresponding sale of shares was pursuant to a Rule 10b5-1 trading plan (the "plan") entered into by the reporting person. The plan is designed to exercise and sell up to 148,138 stock options (which expire at the end of 2019) during the month of January 2019, in equal tranches of approximately 7,055 shares per day assuming certain conditions are met. F2 · price: This transaction was executed in multiple trades at prices ranging from $114.73 to $115.72. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 31, 2019 Filed Feb 1, 2019 13:54 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 7,054 | $52.65 | $371,393.10 |
DisclosureSEC source: 0001127602-19-003268 · form4.xml · nonDerivative · entry 1 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,194 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and corresponding sale of shares was pursuant to a Rule 10b5-1 trading plan (the "plan") entered into by the reporting person. The plan is designed to exercise and sell up to 148,138 stock options (which expire at the end of 2019) during the month of January 2019, in equal tranches of approximately 7,055 shares per day assuming certain conditions are met. Read SEC document |
| January 30, 2019 Filed Jan 31, 2019 13:19 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionStock Options · Derivative | 7,054 | $0.00 Strike: $52.65 | $0.00 |
DisclosureSEC source: 0001127602-19-003132 · form4.xml · derivative · entry 10 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,164 Underlying: Common Stock · 7,054 shares Expires 2019-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and corresponding sale of shares was pursuant to a Rule 10b5-1 trading plan (the "plan") entered into by the reporting person. The plan is designed to exercise and sell up to 148,138 stock options (which expire at the end of 2019) during the month of January 2019, in equal tranches of approximately 7,055 shares per day assuming certain conditions are met. Read SEC document |
| January 30, 2019 Filed Jan 31, 2019 13:19 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 2,869 | $116.19 | $333,352.55 |
DisclosureSEC source: 0001127602-19-003132 · form4.xml · nonDerivative · entry 6 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140 F1 · kind: This exercise of stock options and corresponding sale of shares was pursuant to a Rule 10b5-1 trading plan (the "plan") entered into by the reporting person. The plan is designed to exercise and sell up to 148,138 stock options (which expire at the end of 2019) during the month of January 2019, in equal tranches of approximately 7,055 shares per day assuming certain conditions are met. F5 · price: This transaction was executed in multiple trades at prices ranging from $115.87 to $116.66. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 30, 2019 Filed Jan 31, 2019 13:19 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 4,185 | $115.61 | $483,807.34 |
DisclosureSEC source: 0001127602-19-003132 · form4.xml · nonDerivative · entry 5 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,009 F1 · kind: This exercise of stock options and corresponding sale of shares was pursuant to a Rule 10b5-1 trading plan (the "plan") entered into by the reporting person. The plan is designed to exercise and sell up to 148,138 stock options (which expire at the end of 2019) during the month of January 2019, in equal tranches of approximately 7,055 shares per day assuming certain conditions are met. F4 · price: This transaction was executed in multiple trades at prices ranging from $114.86 to $115.85. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 30, 2019 Filed Jan 31, 2019 13:19 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 7,054 | $52.65 | $371,393.10 |
DisclosureSEC source: 0001127602-19-003132 · form4.xml · nonDerivative · entry 4 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,194 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and corresponding sale of shares was pursuant to a Rule 10b5-1 trading plan (the "plan") entered into by the reporting person. The plan is designed to exercise and sell up to 148,138 stock options (which expire at the end of 2019) during the month of January 2019, in equal tranches of approximately 7,055 shares per day assuming certain conditions are met. Read SEC document |
| January 29, 2019 Filed Jan 31, 2019 13:19 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionStock Options · Derivative | 7,054 | $0.00 Strike: $52.65 | $0.00 |
DisclosureSEC source: 0001127602-19-003132 · form4.xml · derivative · entry 9 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,218 Underlying: Common Stock · 7,054 shares Expires 2019-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and corresponding sale of shares was pursuant to a Rule 10b5-1 trading plan (the "plan") entered into by the reporting person. The plan is designed to exercise and sell up to 148,138 stock options (which expire at the end of 2019) during the month of January 2019, in equal tranches of approximately 7,055 shares per day assuming certain conditions are met. Read SEC document |
| January 29, 2019 Filed Jan 31, 2019 13:19 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 700 | $116.41 | $81,487.98 |
DisclosureSEC source: 0001127602-19-003132 · form4.xml · nonDerivative · entry 3 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140 F1 · kind: This exercise of stock options and corresponding sale of shares was pursuant to a Rule 10b5-1 trading plan (the "plan") entered into by the reporting person. The plan is designed to exercise and sell up to 148,138 stock options (which expire at the end of 2019) during the month of January 2019, in equal tranches of approximately 7,055 shares per day assuming certain conditions are met. F3 · price: This transaction was executed in multiple trades at prices ranging from $116.12 to $116.57. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 29, 2019 Filed Jan 31, 2019 13:19 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 6,354 | $115.63 | $734,688.24 |
DisclosureSEC source: 0001127602-19-003132 · form4.xml · nonDerivative · entry 2 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 840 F1 · kind: This exercise of stock options and corresponding sale of shares was pursuant to a Rule 10b5-1 trading plan (the "plan") entered into by the reporting person. The plan is designed to exercise and sell up to 148,138 stock options (which expire at the end of 2019) during the month of January 2019, in equal tranches of approximately 7,055 shares per day assuming certain conditions are met. F2 · price: This transaction was executed in multiple trades at prices ranging from $115.10 to $115.99. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 29, 2019 Filed Jan 31, 2019 13:19 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 7,054 | $52.65 | $371,393.10 |
DisclosureSEC source: 0001127602-19-003132 · form4.xml · nonDerivative · entry 1 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,194 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and corresponding sale of shares was pursuant to a Rule 10b5-1 trading plan (the "plan") entered into by the reporting person. The plan is designed to exercise and sell up to 148,138 stock options (which expire at the end of 2019) during the month of January 2019, in equal tranches of approximately 7,055 shares per day assuming certain conditions are met. Read SEC document |
| January 28, 2019 Filed Jan 29, 2019 13:20 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionStock Options · Derivative | 7,054 | $0.00 Strike: $52.65 | $0.00 |
DisclosureSEC source: 0001127602-19-002842 · form4.xml · derivative · entry 12 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,272 Underlying: Common Stock · 7,054 shares Expires 2019-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and corresponding sale of shares was pursuant to a Rule 10b5-1 trading plan (the "plan") entered into by the reporting person. The plan is designed to exercise and sell up to 148,138 stock options (which expire at the end of 2019) during the month of January 2019, in equal tranches of approximately 7,055 shares per day assuming certain conditions are met. Read SEC document |
| January 28, 2019 Filed Jan 29, 2019 13:20 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 2,927 | $116.13 | $339,905.19 |
DisclosureSEC source: 0001127602-19-002842 · form4.xml · nonDerivative · entry 8 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140 F1 · kind: This exercise of stock options and corresponding sale of shares was pursuant to a Rule 10b5-1 trading plan (the "plan") entered into by the reporting person. The plan is designed to exercise and sell up to 148,138 stock options (which expire at the end of 2019) during the month of January 2019, in equal tranches of approximately 7,055 shares per day assuming certain conditions are met. F7 · price: This transaction was executed in multiple trades at prices ranging from $115.75 to $116.43. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 28, 2019 Filed Jan 29, 2019 13:20 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 3,427 | $115.33 | $395,233.85 |
DisclosureSEC source: 0001127602-19-002842 · form4.xml · nonDerivative · entry 7 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,067 F1 · kind: This exercise of stock options and corresponding sale of shares was pursuant to a Rule 10b5-1 trading plan (the "plan") entered into by the reporting person. The plan is designed to exercise and sell up to 148,138 stock options (which expire at the end of 2019) during the month of January 2019, in equal tranches of approximately 7,055 shares per day assuming certain conditions are met. F6 · price: This transaction was executed in multiple trades at prices ranging from $114.75 to $115.69. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 28, 2019 Filed Jan 29, 2019 13:20 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 700 | $114.43 | $80,098.48 |
DisclosureSEC source: 0001127602-19-002842 · form4.xml · nonDerivative · entry 6 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,494 F1 · kind: This exercise of stock options and corresponding sale of shares was pursuant to a Rule 10b5-1 trading plan (the "plan") entered into by the reporting person. The plan is designed to exercise and sell up to 148,138 stock options (which expire at the end of 2019) during the month of January 2019, in equal tranches of approximately 7,055 shares per day assuming certain conditions are met. F5 · price: This transaction was executed in multiple trades at prices ranging from $113.66 to $114.64. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 28, 2019 Filed Jan 29, 2019 13:20 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 7,054 | $52.65 | $371,393.10 |
DisclosureSEC source: 0001127602-19-002842 · form4.xml · nonDerivative · entry 5 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,194 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and corresponding sale of shares was pursuant to a Rule 10b5-1 trading plan (the "plan") entered into by the reporting person. The plan is designed to exercise and sell up to 148,138 stock options (which expire at the end of 2019) during the month of January 2019, in equal tranches of approximately 7,055 shares per day assuming certain conditions are met. Read SEC document |
| January 25, 2019 Filed Jan 29, 2019 13:20 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionStock Options · Derivative | 7,054 | $0.00 Strike: $52.65 | $0.00 |
DisclosureSEC source: 0001127602-19-002842 · form4.xml · derivative · entry 11 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,326 Underlying: Common Stock · 7,054 shares Expires 2019-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and corresponding sale of shares was pursuant to a Rule 10b5-1 trading plan (the "plan") entered into by the reporting person. The plan is designed to exercise and sell up to 148,138 stock options (which expire at the end of 2019) during the month of January 2019, in equal tranches of approximately 7,055 shares per day assuming certain conditions are met. Read SEC document |
| January 25, 2019 Filed Jan 29, 2019 13:20 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 3,853 | $115.66 | $445,637.59 |
DisclosureSEC source: 0001127602-19-002842 · form4.xml · nonDerivative · entry 4 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140 F1 · kind: This exercise of stock options and corresponding sale of shares was pursuant to a Rule 10b5-1 trading plan (the "plan") entered into by the reporting person. The plan is designed to exercise and sell up to 148,138 stock options (which expire at the end of 2019) during the month of January 2019, in equal tranches of approximately 7,055 shares per day assuming certain conditions are met. F4 · price: This transaction was executed in multiple trades at prices ranging from $115.13 to $115.96. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 25, 2019 Filed Jan 29, 2019 13:20 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 3,001 | $114.64 | $344,036.44 |
DisclosureSEC source: 0001127602-19-002842 · form4.xml · nonDerivative · entry 3 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,993 F1 · kind: This exercise of stock options and corresponding sale of shares was pursuant to a Rule 10b5-1 trading plan (the "plan") entered into by the reporting person. The plan is designed to exercise and sell up to 148,138 stock options (which expire at the end of 2019) during the month of January 2019, in equal tranches of approximately 7,055 shares per day assuming certain conditions are met. F3 · price: This transaction was executed in multiple trades at prices ranging from $114.00 to $114.94. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 25, 2019 Filed Jan 29, 2019 13:20 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 200 | $113.42 | $22,684.50 |
DisclosureSEC source: 0001127602-19-002842 · form4.xml · nonDerivative · entry 2 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,994 F1 · kind: This exercise of stock options and corresponding sale of shares was pursuant to a Rule 10b5-1 trading plan (the "plan") entered into by the reporting person. The plan is designed to exercise and sell up to 148,138 stock options (which expire at the end of 2019) during the month of January 2019, in equal tranches of approximately 7,055 shares per day assuming certain conditions are met. F2 · price: This transaction was executed in multiple trades at prices ranging from $112.935 to $113.91. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 25, 2019 Filed Jan 29, 2019 13:20 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 7,054 | $52.65 | $371,393.10 |
DisclosureSEC source: 0001127602-19-002842 · form4.xml · nonDerivative · entry 1 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,194 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and corresponding sale of shares was pursuant to a Rule 10b5-1 trading plan (the "plan") entered into by the reporting person. The plan is designed to exercise and sell up to 148,138 stock options (which expire at the end of 2019) during the month of January 2019, in equal tranches of approximately 7,055 shares per day assuming certain conditions are met. Read SEC document |
| January 24, 2019 Filed Jan 25, 2019 13:14 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionStock Options · Derivative | 7,054 | $0.00 Strike: $52.65 | $0.00 |
DisclosureSEC source: 0001127602-19-002688 · form4.xml · derivative · entry 13 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,380 Underlying: Common Stock · 7,054 shares Expires 2019-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and corresponding sale of shares was pursuant to a Rule 10b5-1 trading plan (the "plan") entered into by the reporting person. The plan is designed to exercise and sell up to 148,138 stock options (which expire at the end of 2019) during the month of January 2019, in equal tranches of approximately 7,055 shares per day assuming certain conditions are met. Read SEC document |
| January 24, 2019 Filed Jan 25, 2019 13:14 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 100 | $115.45 | $11,545.00 |
DisclosureSEC source: 0001127602-19-002688 · form4.xml · nonDerivative · entry 9 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140 F1 · kind: This exercise of stock options and corresponding sale of shares was pursuant to a Rule 10b5-1 trading plan (the "plan") entered into by the reporting person. The plan is designed to exercise and sell up to 148,138 stock options (which expire at the end of 2019) during the month of January 2019, in equal tranches of approximately 7,055 shares per day assuming certain conditions are met. Read SEC document |
| January 24, 2019 Filed Jan 25, 2019 13:14 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 1,660 | $114.75 | $190,477.86 |
DisclosureSEC source: 0001127602-19-002688 · form4.xml · nonDerivative · entry 8 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 240 F1 · kind: This exercise of stock options and corresponding sale of shares was pursuant to a Rule 10b5-1 trading plan (the "plan") entered into by the reporting person. The plan is designed to exercise and sell up to 148,138 stock options (which expire at the end of 2019) during the month of January 2019, in equal tranches of approximately 7,055 shares per day assuming certain conditions are met. F7 · price: This transaction was executed in multiple trades at prices ranging from $114.34 to $115.20. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 24, 2019 Filed Jan 25, 2019 13:14 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 5,294 | $113.67 | $601,756.80 |
DisclosureSEC source: 0001127602-19-002688 · form4.xml · nonDerivative · entry 7 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,900 F1 · kind: This exercise of stock options and corresponding sale of shares was pursuant to a Rule 10b5-1 trading plan (the "plan") entered into by the reporting person. The plan is designed to exercise and sell up to 148,138 stock options (which expire at the end of 2019) during the month of January 2019, in equal tranches of approximately 7,055 shares per day assuming certain conditions are met. F6 · price: This transaction was executed in multiple trades at prices ranging from $113.32 to $114.29. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 24, 2019 Filed Jan 25, 2019 13:14 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 7,054 | $52.65 | $371,393.10 |
DisclosureSEC source: 0001127602-19-002688 · form4.xml · nonDerivative · entry 6 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,194 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and corresponding sale of shares was pursuant to a Rule 10b5-1 trading plan (the "plan") entered into by the reporting person. The plan is designed to exercise and sell up to 148,138 stock options (which expire at the end of 2019) during the month of January 2019, in equal tranches of approximately 7,055 shares per day assuming certain conditions are met. Read SEC document |
| January 23, 2019 Filed Jan 25, 2019 13:14 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionStock Options · Derivative | 7,054 | $0.00 Strike: $52.65 | $0.00 |
DisclosureSEC source: 0001127602-19-002688 · form4.xml · derivative · entry 12 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,434 Underlying: Common Stock · 7,054 shares Expires 2019-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and corresponding sale of shares was pursuant to a Rule 10b5-1 trading plan (the "plan") entered into by the reporting person. The plan is designed to exercise and sell up to 148,138 stock options (which expire at the end of 2019) during the month of January 2019, in equal tranches of approximately 7,055 shares per day assuming certain conditions are met. Read SEC document |
| January 23, 2019 Filed Jan 25, 2019 13:14 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 999 | $114.45 | $114,338.45 |
DisclosureSEC source: 0001127602-19-002688 · form4.xml · nonDerivative · entry 5 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140 F1 · kind: This exercise of stock options and corresponding sale of shares was pursuant to a Rule 10b5-1 trading plan (the "plan") entered into by the reporting person. The plan is designed to exercise and sell up to 148,138 stock options (which expire at the end of 2019) during the month of January 2019, in equal tranches of approximately 7,055 shares per day assuming certain conditions are met. F5 · price: This transaction was executed in multiple trades at prices ranging from $114.15 to $114.96. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 23, 2019 Filed Jan 25, 2019 13:14 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 2,100 | $113.67 | $238,700.70 |
DisclosureSEC source: 0001127602-19-002688 · form4.xml · nonDerivative · entry 4 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,139 F1 · kind: This exercise of stock options and corresponding sale of shares was pursuant to a Rule 10b5-1 trading plan (the "plan") entered into by the reporting person. The plan is designed to exercise and sell up to 148,138 stock options (which expire at the end of 2019) during the month of January 2019, in equal tranches of approximately 7,055 shares per day assuming certain conditions are met. F4 · price: This transaction was executed in multiple trades at prices ranging from $113.125 to $114.11. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 23, 2019 Filed Jan 25, 2019 13:14 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 2,555 | $112.63 | $287,764.28 |
DisclosureSEC source: 0001127602-19-002688 · form4.xml · nonDerivative · entry 3 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,239 F1 · kind: This exercise of stock options and corresponding sale of shares was pursuant to a Rule 10b5-1 trading plan (the "plan") entered into by the reporting person. The plan is designed to exercise and sell up to 148,138 stock options (which expire at the end of 2019) during the month of January 2019, in equal tranches of approximately 7,055 shares per day assuming certain conditions are met. F3 · price: This transaction was executed in multiple trades at prices ranging from $112.08 to $112.90. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 23, 2019 Filed Jan 25, 2019 13:14 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 1,400 | $111.36 | $155,905.96 |
DisclosureSEC source: 0001127602-19-002688 · form4.xml · nonDerivative · entry 2 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,794 F1 · kind: This exercise of stock options and corresponding sale of shares was pursuant to a Rule 10b5-1 trading plan (the "plan") entered into by the reporting person. The plan is designed to exercise and sell up to 148,138 stock options (which expire at the end of 2019) during the month of January 2019, in equal tranches of approximately 7,055 shares per day assuming certain conditions are met. F2 · price: This transaction was executed in multiple trades at prices ranging from $110.81 to $111.62. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 23, 2019 Filed Jan 25, 2019 13:14 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 7,054 | $52.65 | $371,393.10 |
DisclosureSEC source: 0001127602-19-002688 · form4.xml · nonDerivative · entry 1 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,194 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and corresponding sale of shares was pursuant to a Rule 10b5-1 trading plan (the "plan") entered into by the reporting person. The plan is designed to exercise and sell up to 148,138 stock options (which expire at the end of 2019) during the month of January 2019, in equal tranches of approximately 7,055 shares per day assuming certain conditions are met. Read SEC document |
| January 22, 2019 Filed Jan 23, 2019 13:28 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionStock Options · Derivative | 7,054 | $0.00 Strike: $52.65 | $0.00 |
DisclosureSEC source: 0001127602-19-002513 · form4.xml · derivative · entry 11 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,488 Underlying: Common Stock · 7,054 shares Expires 2019-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and corresponding sale of shares was pursuant to a Rule 10b5-1 trading plan (the "plan") entered into by the reporting person. The plan is designed to exercise and sell up to 148,138 stock options (which expire at the end of 2019) during the month of January 2019, in equal tranches of approximately 7,055 shares per day assuming certain conditions are met. Read SEC document |
| January 22, 2019 Filed Jan 23, 2019 13:28 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 100 | $115.15 | $11,515.00 |
DisclosureSEC source: 0001127602-19-002513 · form4.xml · nonDerivative · entry 7 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140 F1 · kind: This exercise of stock options and corresponding sale of shares was pursuant to a Rule 10b5-1 trading plan (the "plan") entered into by the reporting person. The plan is designed to exercise and sell up to 148,138 stock options (which expire at the end of 2019) during the month of January 2019, in equal tranches of approximately 7,055 shares per day assuming certain conditions are met. Read SEC document |
| January 22, 2019 Filed Jan 23, 2019 13:28 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 1,959 | $113.72 | $222,773.76 |
DisclosureSEC source: 0001127602-19-002513 · form4.xml · nonDerivative · entry 6 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 240 F1 · kind: This exercise of stock options and corresponding sale of shares was pursuant to a Rule 10b5-1 trading plan (the "plan") entered into by the reporting person. The plan is designed to exercise and sell up to 148,138 stock options (which expire at the end of 2019) during the month of January 2019, in equal tranches of approximately 7,055 shares per day assuming certain conditions are met. F5 · price: This transaction was executed in multiple trades at prices ranging from $113.52 to $114.16. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 22, 2019 Filed Jan 23, 2019 13:28 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 4,995 | $113.17 | $565,302.13 |
DisclosureSEC source: 0001127602-19-002513 · form4.xml · nonDerivative · entry 5 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,199 F1 · kind: This exercise of stock options and corresponding sale of shares was pursuant to a Rule 10b5-1 trading plan (the "plan") entered into by the reporting person. The plan is designed to exercise and sell up to 148,138 stock options (which expire at the end of 2019) during the month of January 2019, in equal tranches of approximately 7,055 shares per day assuming certain conditions are met. F4 · price: This transaction was executed in multiple trades at prices ranging from $112.52 to $113.50. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 22, 2019 Filed Jan 23, 2019 13:28 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 7,054 | $52.65 | $371,393.10 |
DisclosureSEC source: 0001127602-19-002513 · form4.xml · nonDerivative · entry 4 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,194 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and corresponding sale of shares was pursuant to a Rule 10b5-1 trading plan (the "plan") entered into by the reporting person. The plan is designed to exercise and sell up to 148,138 stock options (which expire at the end of 2019) during the month of January 2019, in equal tranches of approximately 7,055 shares per day assuming certain conditions are met. Read SEC document |
| January 18, 2019 Filed Jan 23, 2019 13:28 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionStock Options · Derivative | 7,054 | $0.00 Strike: $52.65 | $0.00 |
DisclosureSEC source: 0001127602-19-002513 · form4.xml · derivative · entry 10 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,542 Underlying: Common Stock · 7,054 shares Expires 2019-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and corresponding sale of shares was pursuant to a Rule 10b5-1 trading plan (the "plan") entered into by the reporting person. The plan is designed to exercise and sell up to 148,138 stock options (which expire at the end of 2019) during the month of January 2019, in equal tranches of approximately 7,055 shares per day assuming certain conditions are met. Read SEC document |
| January 18, 2019 Filed Jan 23, 2019 13:28 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 1,239 | $115.57 | $143,194.95 |
DisclosureSEC source: 0001127602-19-002513 · form4.xml · nonDerivative · entry 3 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140 F1 · kind: This exercise of stock options and corresponding sale of shares was pursuant to a Rule 10b5-1 trading plan (the "plan") entered into by the reporting person. The plan is designed to exercise and sell up to 148,138 stock options (which expire at the end of 2019) during the month of January 2019, in equal tranches of approximately 7,055 shares per day assuming certain conditions are met. F3 · price: This transaction was executed in multiple trades at prices ranging from $115.53 to $115.70. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.